Moleculin Biotech (MBRX) Enterprise Value (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Enterprise Value of -$8.9 million for Q4 2025, down 107.53% year-over-year from $118.0 million in Q4 2024, and down 32.45% quarter-over-quarter from -$6.7 million in Q3 2025.
Moleculin Biotech (MBRX) Enterprise Value (2015 - 2026) Analysis & Trends
Moleculin Biotech's Enterprise Value history runs 11 years deep, the most recent figure standing at -$8.9 million for Q4 2025.
- In Q4 2025, Enterprise Value fell 107.53% year-over-year to -$8.9 million; the TTM figure through Dec 2025 stood at -$8.9 million (down 107.53% YoY), while the FY2025 annual figure was -$8.9 million, down 107.53% from the prior year.
- Enterprise Value for Q4 2025 stood at -$8.9 million, down from -$6.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$4.3 million in Q4 2024, with the low at -$86.3 million in Q1 2021.
- The 5-year median for Enterprise Value is -$28.4 million (2023), against an average of -$36.0 million.
- The sharpest annual moves came in 2021 and 2024: Enterprise Value tumbled 640.78% in 2021, then jumped 81.83% in 2024.
- Moleculin Biotech's Enterprise Value stood at -$70.9 million in 2021, then soared by 39.15% to -$43.1 million in 2022, then soared by 45.42% to -$23.6 million in 2023, then surged by 81.83% to -$4.3 million in 2024, then tumbled by 107.53% to -$8.9 million in 2025.
- Business Quant data shows MBRX's Enterprise Value at -$8.9 million in Q4 2025, -$6.7 million in Q3 2025, and -$7.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | -7.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.26 Mn |
| Dec 31, 2025 | -8.88 Mn |
| Sep 30, 2025 | -6.70 Mn |
| Jun 30, 2025 | -7.56 Mn |
| Mar 31, 2025 | -7.72 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -9.41 Mn |
| Jun 30, 2024 | -10.85 Mn |
| Mar 31, 2024 | -16.82 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -24.60 Mn |
| Jun 30, 2023 | -32.20 Mn |
| Mar 31, 2023 | -37.27 Mn |
| Dec 31, 2022 | -43.15 Mn |
| Sep 30, 2022 | -50.40 Mn |
| Jun 30, 2022 | -58.00 Mn |
| Mar 31, 2022 | -66.10 Mn |
| Dec 31, 2021 | -70.90 Mn |
| Sep 30, 2021 | -75.20 Mn |
| Jun 30, 2021 | -79.50 Mn |